| **Table 2 Demographic and Clinical Characteristics by Gender** | | | |
| --- | --- | --- | --- |
|  | **Female n (%)** | **Male n (%)** | **Total n (%)** |
| Count | 220,197 (46.7%) | 251,719 (53.3%) | 471,916 (100%) |
|  |  |  |  |
| Age category |  |  |  |
| 0 to 2 Years | 9,440 (4.3%) | 11,767 (4.7%) | 21,207 (4.5%) |
| 3 to 12 Years | 9,132 (4.1%) | 9,749 (3.9%) | 18,881 (4%) |
| 13 to 18 Years | 5,647 (2.6%) | 6,156 (2.4%) | 11,803 (2.5%) |
| 19 to 64 Years | 104,618 (47.5%) | 123,186 (48.9%) | 227,804 (48.3%) |
| 65 to 84 Years | 69,979 (31.8%) | 85,010 (33.8%) | 154,989 (32.8%) |
| 85 and Over | 21,381 (9.7%) | 15,851 (6.3%) | 37,232 (7.9%) |
|  |  |  |  |
| Resistance status1 |  |  |  |
| Escherichia coli (Ampicillin) | 36,787/57,655 (63.8%) | 34,095/50,959 (66.9%) | 70,882/108,614 (65.3%) |
| Escherichia coli (Levofloxacin) | 19,898/57,655 (34.5%) | 19,633/50,959 (38.5%) | 39,531/108,614 (36.4%) |
| Staphylococcus aureus (Erythromycin) | 17,735/42,016 (42.2%) | 26,427/60,613 (43.6%) | 44,162/102,629 (43%) |
| Staphylococcus aureus (Levofloxacin) | 20,285/62,871 (32.3%) | 30,611/89,188 (34.3%) | 50,896/152,059 (33.5%) |
|  |  |  |  |
| 1Resistant isolates/total tested (% resistant) | | | |